About Javeri
Product & Services
Equity
Derivatives
Mutual Funds
IPO
Corporate Info
Research
Contact Us
Corporate Info
Smart Quotes
Company Background
Board of Directors
Balance Sheet
Profit & Loss
Peer Comparison
Cash Flow
Shareholdings Pattern
Quarterly Results
Share Price
Deliverable Volume
Historical Volume
MF Holdings
Financial Ratios
Directors Report
Price Charts
Notes Of Account
Management Discussion
Beta Analysis
Board Meetings
Corporate Announcements
Book Closure
Record Date
Bonus
Company News
Bulk Deals
Block Deals
Monthly High/low
Dividend Details
Bulk Deals
Insider Trading
Advanced Chart
HOME
>
CORPORATE INFO
>
COMPANY NEWS
Company
News
Lupin Ltd.
Change Company
BSE Code
500257
ISIN Demat
INE326A01037
Book Value
481.73
NSE Code
LUPIN
Dividend Yield %
0.37
Market Cap
979786.49
P/E
32.69
EPS
65.70
Face Value
2
1 Week
1 Month
3 Months
6 Months
1 Year
19-Dec-2024
Lupin gets USFDA’s nod for Emtricitabine and Teno...
19-Dec-2024
Lupin moves up on getting USFDA’s nod for Emtrici...
13-Dec-2024
Lupin acquires trademarks from Boehringer Ingelhe...
09-Dec-2024
Lupin informs about disclosures
02-Dec-2024
Clarification /Confirmation On The News Item App...
26-Nov-2024
Lupin’s arm recalling over 6 lakh bottles of Rami...
08-Nov-2024
Lupin reports 74% rise in Q2 consolidated net pro...
08-Nov-2024
Lupin inches up on reporting 74% rise in Q2 conso...
23-Oct-2024
Lupin informs about allotment of shares under ESOP
15-Oct-2024
Lupin launches first generic version of Pred Fort...
15-Oct-2024
Lupin inches up on launching first generic versio...
15-Oct-2024
Lupin informs about press release
09-Oct-2024
Lupin informs about details of loss of certificat...
07-Oct-2024
USFDA completes pre-approval inspection at Lupin’...
05-Oct-2024
Lupin informs about disclosure
Page
1
of
6
Prev
||
Next
Disclaimer
|
Privacy Policy
| Grievance |
FAQ
|
Sitemap |
Client Registration |
Useful Links
|
Anti Money Laundering
|
Inactive Client Policy
|
Scores
Vernacular Kyc
|
Advisory For Investors
|
Investor Adviser
|
Filing complaints on SCORES - Easy & quick
|
Policy on PMLA
Publishing of investor charter information
|
Annexure A – Investor charter of brokers
|
Annexure A – Investor charter of DP
|
Annexure B –Linked content for information to charter for DP
|
Annexure B & C (investor complaint data) broker & DP
Investor Charter & Complaints
|
Advisory-KYC Compliance
|
E-Voting NSE
|
E-Voting BSE
|
Details of Client Bank Accounts
|
Risk Disclosure
|
NSE FO Risk disclosure
SEBI Regn. No.: INB010997431 (BSE), INB230997430 (NSE)
Copyright 2008 Javeri Fiscal Services Ltd.
Designed , Developed & Content Powered by
Accord Fintech Pvt. Ltd.
CLOSE
X
RISK DISCLOSURES ON DERIVATIVES
9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
On an average, loss makers registered net trading loss close to ₹ 50,000.
Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Source:
Click Here.